| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
198.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $11.83 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
28,404 |
81,669 |
102,627 |
249,047 |
| Total Sell Value |
$143,555 |
$483,399 |
$698,702 |
$3,966,152 |
| Total People Sold |
11 |
12 |
13 |
14 |
| Total Sell Transactions |
11 |
14 |
16 |
52 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Astley-Sparke Philip |
Director |
– • – |
2019-08-01 |
4 |
AS |
$58.15 |
$388,344 |
D/D |
(6,460) |
6,812 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-07-17 |
4 |
AS |
$70.00 |
$571,616 |
D/D |
(8,000) |
399,230 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-06-19 |
4 |
AS |
$77.26 |
$619,626 |
D/D |
(8,000) |
407,230 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2019-06-03 |
4 |
AS |
$61.40 |
$381,779 |
D/D |
(6,000) |
13,272 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-05-15 |
4 |
AS |
$57.46 |
$467,017 |
D/D |
(8,000) |
415,230 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2019-04-16 |
4 |
S |
$57.18 |
$88,400 |
D/D |
(1,546) |
54,539 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2019-04-01 |
4 |
AS |
$59.84 |
$359,040 |
D/D |
(6,000) |
19,272 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-03-14 |
4 |
AS |
$62.65 |
$1,242,081 |
D/D |
(19,688) |
423,230 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-03-13 |
4 |
AS |
$63.75 |
$3,067,216 |
D/D |
(47,688) |
442,918 |
|
- |
|
| Kuta Alexander Edward Iii |
SVP, Regulatory Affairs |
• – – |
2019-02-15 |
4 |
AS |
$35.80 |
$286,560 |
D/D |
(8,000) |
38,578 |
|
- |
|
| Kuta Alexander Edward Iii |
SVP, Regulatory Affairs |
• – – |
2019-02-15 |
4 |
OE |
$5.31 |
$106,200 |
D/D |
20,000 |
46,578 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.31 |
$37,885 |
D/D |
(1,210) |
14,934 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.32 |
$37,897 |
D/D |
(1,210) |
19,934 |
|
- |
|
| Van Deventer Sander |
Chief Scientific Officer |
• – – |
2019-01-28 |
4 |
S |
$31.31 |
$42,519 |
D/D |
(1,358) |
40,313 |
|
- |
|
| Schaffer David |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.31 |
$37,885 |
D/D |
(1,210) |
45,721 |
|
- |
|
| Kuta Alexander Edward Iii |
SVP, Regulatory Affairs |
• – – |
2019-01-28 |
4 |
S |
$31.29 |
$32,917 |
D/D |
(1,052) |
26,578 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.32 |
$37,897 |
D/D |
(1,210) |
25,272 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2019-01-28 |
4 |
S |
$31.29 |
$46,278 |
D/D |
(1,479) |
56,085 |
|
- |
|
| Mcmillan Scott T. |
Chief Operating Officer |
• – – |
2019-01-28 |
4 |
S |
$31.23 |
$18,457 |
D/D |
(591) |
20,432 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.32 |
$37,897 |
D/D |
(1,210) |
6,812 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-01-28 |
4 |
AS |
$31.42 |
$599,651 |
D/D |
(19,085) |
490,028 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.31 |
$37,885 |
D/D |
(1,210) |
6,812 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
16,144 |
|
- |
|
| Gut Robert |
Chief Medical Officer |
• • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,147 |
40,147 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
26,482 |
|
- |
|
336 Records found
|
|
Page 11 of 14 |
|
|
0.08 (1.76%) 
